DNAPrint Selects Proteos to Manufacture PT-401 for Pre-Clinical Evaluation

DNAPrint Selects Proteos to Manufacture PT-401 for Pre-Clinical
Evaluation 


SARASOTA, Fla., June 14  /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC:DNAP) (BULLETIN BOARD: DNAP)  (the "Company") today announced that it has
selected Proteos, Inc. to manufacture the first batch of its new therapeutic
candidate PT-401 (Super EPO dimer) for pre-clinical testing.

"Proteos has 20 years of experience in protein and peptide chemistry and has
proven its ability as a Contract Research Organization (CRO) dealing with
biologically complex therapeutics," stated DNAPrint Chairman and Chief Medical
Officer Hector Gomez, M.D., Ph.D. "The selection of Proteos is the culmination
of a competitive bidding process solicited by DNAPrint management.  In
addition, Proteos' staff has previously worked with erythropoietin (EPO), the
simpler, monomer form of the drug that major pharmaceutical companies currently
have on the market."

DNAPrint announced in April that it has acquired an exclusive worldwide license
from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) to
develop a new, more potent and longer acting form of the anemia drug
erythropoietin. DNAPrint is working on the project with Dr. Arthur J.
Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division
of Hematology and Oncology at Beth Israel Deaconess. The PT-401 to be
manufactured by Proteos will be used to generate pre-clinical data required for
an Investigational New Drug (IND) application as required by the U.S. Food and
Drug Administration.

"We are now beginning the clinical development process and today's announcement
is a major step for DNAPrint toward compiling the data for its first IND
application," stated President and Chief Executive Officer Richard Gabriel. 
"Dr. Sytkowski, who has worked his entire career on Erythropoietin and similar
molecules, and Dr. Gomez selected Proteos for its technical skills and
background and will monitor the data collection very closely."

DNAPrint also announced that it has agreed to a six-month contract with Dr.
Sytkowski to provide continued support for the completion of the PT-401
clinical research program.  "Dr. Sytkowski holds eight patents covering this
technology and is the author of a book on the subject, 'Erythropoietin, Blood,
Brain and Beyond.'  He brings a knowledge base to the development of our
licensed product, and his agreement is structured to give him appropriate
incentives to help move the product through clinical development," Dr. Gomez
stated.

About Proteos

Proteos, Inc. ( http://www.proteos.net/ ) is a provider of high quality
proteins and peptides for enabling and facilitating drug discovery.  The
Proteos Process includes target identification, expression using various cell
lines, purification and production of proteins. Unique protein services include
Expression in baculovirus, mammalian cells, and E coli, Refolding of proteins
from inclusion bodies, Purification, and Assay Development.  Peptide services
include Design and Modification, and Antigen Design, Production and
Purification. Proteos, based in Kalamazoo, Mich., was founded by eight
scientists following the August 2002 acquisition of Pharmacia by Pfizer, Inc.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of
genomics-based products and services focused on drug development,
pharmacogenomic diagnostic tests, forensics technology and consumer genetic
tests. The Company's first theranostic product (drug/test combination) is
PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of
anemia in renal dialysis patients (end stage renal disease). Currently in
pre-clinical development, PT-401 will be targeted to patients with a genetic
profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward-
looking statements. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected,
including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory approvals,
competition, intellectual property of others, and patent protection and
litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-
looking statements contained herein to reflect any change in DNAPrint's
expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based.

   Company Contact:
   Richard Gabriel
   President and CEO
   941-366-3400
        -or-
   Ron Stabiner
   The Wall Street Group, Inc.
   212-888-4848


DATASOURCE: DNAPrint genomics, Inc.



CONTACT:  Richard Gabriel, President and CEO of DNAPrint genomics,

[phone], or Ron Stabiner of The Wall Street Group, Inc.,

[phone], for DNAPrint



Web site:  http://www.dnaprint.com/

http://www.proteos.net/ 

Copyright